JPWO2020006242A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020006242A5 JPWO2020006242A5 JP2020572793A JP2020572793A JPWO2020006242A5 JP WO2020006242 A5 JPWO2020006242 A5 JP WO2020006242A5 JP 2020572793 A JP2020572793 A JP 2020572793A JP 2020572793 A JP2020572793 A JP 2020572793A JP WO2020006242 A5 JPWO2020006242 A5 JP WO2020006242A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- peptide epitopes
- epitopes
- epitope
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 41
- 108020004707 nucleic acids Proteins 0.000 claims 39
- 238000009566 cancer vaccine Methods 0.000 claims 36
- 230000035772 mutation Effects 0.000 claims 25
- 102000027675 major histocompatibility complex family Human genes 0.000 claims 24
- 201000011510 cancer Diseases 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 14
- 102000038129 antigens Human genes 0.000 claims 14
- 108091007172 antigens Proteins 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 11
- 108020004999 Messenger RNA Proteins 0.000 claims 6
- 210000004027 cells Anatomy 0.000 claims 6
- 229920002106 messenger RNA Polymers 0.000 claims 6
- 230000001093 anti-cancer Effects 0.000 claims 5
- 230000014509 gene expression Effects 0.000 claims 4
- 229960005486 vaccines Drugs 0.000 claims 4
- 101700020122 DRB1 Proteins 0.000 claims 3
- 101700016627 DRB8 Proteins 0.000 claims 3
- 102100020458 HLA-A Human genes 0.000 claims 3
- 108010075704 HLA-A Antigens Proteins 0.000 claims 3
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 3
- 102100019471 PIK3CA Human genes 0.000 claims 3
- 101710027440 PIK3CA Proteins 0.000 claims 3
- 102100001312 RBM45 Human genes 0.000 claims 3
- 101700059484 RBM45 Proteins 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 2
- 102100020459 HLA-B Human genes 0.000 claims 2
- 108010058607 HLA-B Antigens Proteins 0.000 claims 2
- 108009000344 Head and Neck Squamous Cell Carcinoma Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 102100019730 TP53 Human genes 0.000 claims 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 2
- 230000000259 anti-tumor Effects 0.000 claims 2
- 238000007385 chemical modification Methods 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 230000033607 mismatch repair Effects 0.000 claims 2
- 239000004114 Ammonium polyphosphate Substances 0.000 claims 1
- 102100004555 BCOR Human genes 0.000 claims 1
- 108060000889 BCOR Proteins 0.000 claims 1
- 101700004551 BRAF Proteins 0.000 claims 1
- 102100004328 BRAF Human genes 0.000 claims 1
- 102100016662 ERBB2 Human genes 0.000 claims 1
- 101700025368 ERBB2 Proteins 0.000 claims 1
- 102000027766 FGFR3 Human genes 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 229920002393 Microsatellite Polymers 0.000 claims 1
- 102100001119 NRAS Human genes 0.000 claims 1
- 101710033916 NRAS Proteins 0.000 claims 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 1
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 210000001550 Testis Anatomy 0.000 claims 1
- 108010081267 Type 3 Fibroblast Growth Factor Receptor Proteins 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 1
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000004083 survival Effects 0.000 claims 1
- -1 transcript abundance Polymers 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690441P | 2018-06-27 | 2018-06-27 | |
| US62/690,441 | 2018-06-27 | ||
| US201862757045P | 2018-11-07 | 2018-11-07 | |
| US62/757,045 | 2018-11-07 | ||
| US201962814200P | 2019-03-05 | 2019-03-05 | |
| US62/814,200 | 2019-03-05 | ||
| US201962855311P | 2019-05-31 | 2019-05-31 | |
| US62/855,311 | 2019-05-31 | ||
| PCT/US2019/039521 WO2020006242A1 (en) | 2018-06-27 | 2019-06-27 | Personalized cancer vaccine epitope selection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529750A JP2021529750A (ja) | 2021-11-04 |
| JPWO2020006242A5 true JPWO2020006242A5 (de) | 2022-07-06 |
Family
ID=68986808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572793A Pending JP2021529750A (ja) | 2018-06-27 | 2019-06-27 | 個別化がんワクチンエピトープの選択 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210268086A1 (de) |
| EP (1) | EP3813848A4 (de) |
| JP (1) | JP2021529750A (de) |
| KR (1) | KR20210038886A (de) |
| CN (1) | CN113365639A (de) |
| AU (1) | AU2019293244A1 (de) |
| CA (1) | CA3104673A1 (de) |
| MX (1) | MX2021000193A (de) |
| SG (1) | SG11202012770RA (de) |
| WO (1) | WO2020006242A1 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| TW201718638A (zh) | 2015-07-21 | 2017-06-01 | 現代治療公司 | 傳染病疫苗 |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| EP3364983A4 (de) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Impfstoffe gegen atemwegevirus |
| EA201891001A1 (ru) | 2015-10-22 | 2018-11-30 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv) |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| WO2018053209A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス， インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018107088A2 (en) | 2016-12-08 | 2018-06-14 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| EP3555289A1 (de) | 2016-12-13 | 2019-10-23 | ModernaTX, Inc. | Rna-affinitätsreinigung |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| MA49913A (fr) | 2017-08-18 | 2021-05-05 | Modernatx Inc | Variants d'arn polymérase |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| JP7275111B2 (ja) | 2017-08-31 | 2023-05-17 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の生成方法 |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| WO2020172239A1 (en) | 2019-02-20 | 2020-08-27 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| JP2021185136A (ja) | 2020-04-22 | 2021-12-09 | ビオエンテッヒ・アールエヌエイ・ファーマシューティカルズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | コロナウイルスワクチン |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| EP4148146A1 (de) | 2021-09-13 | 2023-03-15 | OncoDNA | Verfahren zur erzeugung von personalisierten neoantigenen eines tumors eines patienten |
| IL311302A (en) | 2021-09-13 | 2024-05-01 | Oncodna | A method for creating a pool of double-stranded DNA encoding tumor neoantigens |
| WO2023154478A1 (en) * | 2022-02-11 | 2023-08-17 | Washington University | Methods of assessing cancer |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| WO2024014770A1 (ko) * | 2022-07-14 | 2024-01-18 | 엠큐렉스 주식회사 | mRNA 백신 및 치료제의 제조를 위한 변형된 RNA |
| WO2024097257A1 (en) * | 2022-10-31 | 2024-05-10 | Gritstone Bio, Inc. | Combination panel cell-free dna monitoring |
| WO2024151811A1 (en) | 2023-01-11 | 2024-07-18 | Modernatx, Inc. | Personalized cancer vaccines |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2946072T3 (es) * | 2011-05-24 | 2023-07-12 | BioNTech SE | Vacunas individualizadas para el cáncer |
| AU2014251207B2 (en) * | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| JP6925980B2 (ja) * | 2015-05-13 | 2021-08-25 | アジェナス インコーポレイテッド | がんの処置および予防のためのワクチン |
| US20190008938A1 (en) * | 2015-07-30 | 2019-01-10 | Modernatx, Inc. | Concatemeric peptide epitope rnas |
| CN108430456B (zh) * | 2015-10-22 | 2022-01-18 | 摩登纳特斯有限公司 | 癌症疫苗 |
| NZ755780A (en) * | 2017-02-01 | 2023-10-27 | Modernatx Inc | Rna cancer vaccines |
-
2019
- 2019-06-27 CA CA3104673A patent/CA3104673A1/en active Pending
- 2019-06-27 SG SG11202012770RA patent/SG11202012770RA/en unknown
- 2019-06-27 US US17/255,949 patent/US20210268086A1/en active Pending
- 2019-06-27 JP JP2020572793A patent/JP2021529750A/ja active Pending
- 2019-06-27 WO PCT/US2019/039521 patent/WO2020006242A1/en unknown
- 2019-06-27 AU AU2019293244A patent/AU2019293244A1/en active Pending
- 2019-06-27 MX MX2021000193A patent/MX2021000193A/es unknown
- 2019-06-27 KR KR1020217002735A patent/KR20210038886A/ko active Search and Examination
- 2019-06-27 CN CN201980055983.XA patent/CN113365639A/zh active Pending
- 2019-06-27 EP EP19826546.4A patent/EP3813848A4/de active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020006242A5 (de) | ||
| US11248264B2 (en) | Individualized vaccines for cancer | |
| US11504419B2 (en) | Individualized vaccines for cancer | |
| RU2019127381A (ru) | Противораковые рнк-вакцины | |
| Cleyle et al. | Immunopeptidomic analyses of colorectal cancers with and without microsatellite instability | |
| Marcu et al. | Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors | |
| EP3892295B1 (de) | Individualisierte impfstoffe gegen krebs | |
| RU2021101603A (ru) | Отбор эпитопов для персонализированной противораковой вакцины | |
| Sharif et al. | In Silico Design of CT26 Polytope and its Surface Display by ClearColi™-Derived Outer Membrane Vesicles as a Cancer Vaccine Candidate Against Colon Carcinoma | |
| RU2018137721A (ru) | Способы прогнозирования применимости белков или белковых фрагментов для иммунотерапии | |
| NZ617217B2 (en) | Individualized vaccines for cancer | |
| NZ718326B2 (en) | Individualized vaccines for cancer |